JAZZ insider trading — Jazz Pharmaceuticals plc
No open-market insider purchases or sales were filed for Jazz Pharmaceuticals plc (JAZZ) in the last 90 days. Other insider transactions — such as stock awards, option exercises or tax withholding — are listed below.
Updated Oct 16, 2026.
Recent JAZZ insider transactions
Every Form 4 filed by Jazz Pharmaceuticals plc officers, directors and 10% owners in the last 90 days, newest first. P = open-market purchase, S = open-market sale; other codes are awards, option exercises, tax withholding or gifts.
| Trade date | Insider | Role | Type | Ownership | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | Gala Renee D | President & CEO | S · Sale · 10b5-1 | Direct | 2,000 | $236.40 | $473K | Form 4 |
| Oct 1, 2026 | Cozadd Bruce C | Director | S · Sale · 10b5-1 | Direct | 6,000 | $230.33 | $1.38M | Form 4 |
| Sep 10, 2026 | Patil Neena M | EVP & Chief Legal Officer | S · Sale · 10b5-1 | Direct | 1,200 | $240.94 | $289K | Form 4 |
| Sep 8, 2026 | Gala Renee D | President & CEO | F · Tax withholding · 10b5-1 | Direct | 1,967 | $246.81 | $485K | Form 4 |
| Sep 8, 2026 | Gala Renee D | President & CEO | S · Sale · 10b5-1 | Direct | 2,000 | $243.03 | $486K | Form 4 |
| Sep 8, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | F · Tax withholding | Direct | 1,427 | $243.01 | $347K | Form 4 |
| Aug 31, 2026 | Henderson Mary Elizabeth | SVP, Technical Operations | F · Tax withholding | Direct | 2,092 | $241.41 | $505K | Form 4 |
| Aug 31, 2026 | Smith Mark Douglas | Director | F · Tax withholding | Direct | 1,706 | $241.42 | $412K | Form 4 |
| Aug 31, 2026 | Riedel Norbert G | Director | F · Tax withholding | Direct | 1,706 | $241.42 | $412K | Form 4 |
| Aug 31, 2026 | Love Ted W | Director | F · Tax withholding | Direct | 743 | $241.41 | $179K | Form 4 |
| Aug 31, 2026 | Hamill Laura | Director | F · Tax withholding | Direct | 1,706 | $241.41 | $412K | Form 4 |
| Aug 31, 2026 | Cook Jennifer E. | Director | F · Tax withholding | Direct | 1,706 | $241.41 | $412K | Form 4 |
| Aug 31, 2026 | Enright Patrick G | Director | F · Tax withholding | Direct | 1,706 | $241.42 | $412K | Form 4 |
| Aug 31, 2026 | Mcsharry Heather Ann | Director | F · Tax withholding | Direct | 1,855 | $241.42 | $448K | Form 4 |
| Aug 31, 2026 | Kennedy Patrick | Director | F · Tax withholding | Direct | 1,855 | $241.41 | $448K | Form 4 |
| Aug 31, 2026 | Winningham Rick E | Director | F · Tax withholding | Direct | 1,706 | $241.42 | $412K | Form 4 |
| Sep 1, 2026 | Cozadd Bruce C | Director | S · Sale · 10b5-1 | Direct | 6,000 | $250.13 | $1.50M | Form 4 |
| Aug 31, 2026 | Cozadd Bruce C | Director | F · Tax withholding · 10b5-1 | Direct | 1,219 | $241.41 | $294K | Form 4 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | M · Option exercise · 10b5-1 | Direct | 57,500 | $125.84 | $7.24M | Form 4 |
| Aug 27, 2026 | Iannone Robert | EVP, Global Head of R&D & CMO | S · Sale · 10b5-1 | Direct | 76,921 | $249.70 | $19.21M | Form 4 |
| Aug 5, 2026 | Pearce Samantha | EVP, Chief Commercial Officer | F · Tax withholding | Direct | 780 | $261.62 | $204K | Form 4 |
| Aug 5, 2026 | Winningham Rick E | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Love Ted W | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Hamill Laura | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Kennedy Patrick | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Smith Mark Douglas | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Cook Jennifer E. | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Mulligan Seamus | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Mcsharry Heather Ann | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Enright Patrick G | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Riedel Norbert G | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 5, 2026 | Cozadd Bruce C | Director | A · Grant/award | Direct | 1,605 | — | — | Form 4 |
| Aug 3, 2026 | Cozadd Bruce C | Director | S · Sale · 10b5-1 | Direct | 6,000 | $252.98 | $1.52M | Form 4 |
JAZZ insider trading FAQ
Are insiders buying JAZZ stock?
Not on the open market. In the last 90 days, Jazz Pharmaceuticals plc insiders made no open-market purchases, and no open-market sales. Purchases with the insider's own money are generally seen as a stronger signal than sales, which happen for many reasons (taxes, diversification, planned 10b5-1 sales).
Who are the insiders trading JAZZ?
No insider bought or sold on the open market in the last 90 days.
Where does JAZZ insider trading data come from?
Every transaction comes from SEC Form 4 filings on EDGAR. Company officers, directors and 10% owners must file a Form 4 within two business days of buying or selling. InsiderBolt reads these filings directly from the SEC.
More stocks with insider activity
Insider trading data is for informational purposes only and is not investment advice. Filings can be amended; always confirm details on SEC EDGAR.